Publications by authors named "Nitya P Raj"
Important progress has been made over the last decade in the classification, imaging, and treatment of neuroendocrine neoplasm (NENs), with several new agents approved for use. Although the treatment options available for patients with well-differentiated neuroendocrine tumors (NETs) have greatly expanded, the rapidly changing landscape has presented several unanswered questions about how best to optimize, sequence, and individualize therapy. Perhaps the most important development over the last decade has been the approval of 177Lu-DOTATATE for treatment of gastroenteropancreatic-NETs, raising questions around optimal sequencing of peptide receptor radionuclide therapy (PRRT) relative to other therapeutic options, the role of re-treatment with PRRT, and whether PRRT can be further optimized through use of dosimetry among other approaches.
View Article and Find Full Text PDFArticle Synopsis
- Metastatic progression is the leading cause of death in cancer patients, yet the specific genomic mechanisms behind it are not well understood.
- Researchers analyzed data from over 25,000 cancer patients in the MSK-MET cohort, discovering connections between genomic changes and how various tumors spread in 50 different cancer types.
- The study revealed that chromosomal instability is linked to metastatic spread in certain cancers (like prostate and lung adenocarcinomas) but not others (like colorectal cancer), providing insights into how these genomic alterations affect cancer progression and spread to specific organs.
Background: Grade 3 gastroenteropancreatic neuroendocrine neoplasms (G3 GEPNENs) are often aggressive, and the optimal treatment is unclear for this subgroup of neuroendocrine neoplasms (NENs). Temozolomide (TEM)-based regimens have been increasingly used to treat grade 1-2 NENs, but their efficacy in G3 NENs remains undetermined. We aimed to assess the clinical efficacy of TEM-containing regimens in advanced grade 3 GEPNENs.
View Article and Find Full Text PDF